Boardroom Alpha
10-K primary document
TVRD · Annual Report (Form 10-K) · Filed March 31, 2026

Tvardi Therapeutics Inc10-K exhibit

tvrd-20251231xex10d23.htm

Exhibit 10.23

TVARDI THERAPEUTICS, INC.

AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

Adopted April 17, 2025

Equity Compensation:

·

Initial option grant upon joining the board: 12,000 shares (provided that for 2025, directors will only receive the initial grant and will not receive the annual grant at the 2025 Annual Meeting of Stockholders)

·

Annual option grant on the date of each annual meeting of stockholders (for directors continuing as directors following the annual meeting): 6,000 shares

The initial option grant will vest over three years in 12 equal quarterly installments, from the date of appointment, subject to the director’s continued service as a director through each such vesting date.

Each annual option grant will vest on the earlier of (1) the one year anniversary of the date of grant and (2) immediately prior to the next annual meeting of stockholders following the date of grant, in each case, subject to the director’s continued service as a director through such date.

Cash Compensation:

·

Annual board retainer fee - $40,000

·

Chairperson or Lead Independent Director (if any) fee - $30,000

·

Audit Committee

o

Chairperson fee (including member fee) - $15,000

o

Member fee - $7,500

·

Compensation Committee

o

Chairperson fee (including member fee) - $12,000

o

Member fee - $6,000

·

Nominating and Corporate Governance Committee

o

Chairperson fee (including member fee) - $10,000

o

Member fee - $5,000

These retainers are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment will be prorated for any portion of such quarter that the director is not serving on the board of directors or applicable committee.

Reimbursement of Expenses:

The Company will reimburse non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending board of director and committee meetings.

1


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer